Chengzhi Shareholding Co.,Ltd Company Profile

08:58 EDT 20th June 2018 | BioPortfolio

Chengzhi Shareholding Co.,Ltd was established on October 8. 1998 in Nanchang, Currently the total asset is 922.18 millions Yuan with 27 subsidiary companies. The company currently has more than 1900 employees with support from Tsinghua University and with several tens of professors, doctors, and masters as backbone, a team of high standard scientific research and management team is driving the ever changing operation of Chengzhi.

Chengzhi Life Science Co.,Ltd in Beijing for biochemical and fine chemical product business, as the subordinate of Chengzhi Shareholding Co.,Ltd., is a medium-sized enterprise which its registration capital is RMB180 million.

As a subsidiary factory of Chengzhi Life Science Co.,Ltd, Jiangxi Chengzhi Bioengineering Company Ltd is located in Jiangxi Province. It occupies an area of 22000m2 with a building area of 15000m2. The factory is built according to the GMP standard, commercial production is carried out in plant operating to ISO 9001:2000 and Koshier by Orthodox Union. The development and production of the L-Glutamine and D-Ribose are in the first place in China.

We have two series main product produced in several chengzhi’s plants routinely. L-Glutamine and D-Ribose, manufactured by Jiangxi Chengzhi Bioengineering Company Ltd , are very popular in international market. The fluorescent brighteners series and fine chemical intermediates series, manufactured by chengzhi’s other chemical plants, are also competitive both at price and quality compare with the other suppliers.


805C#, Dongsheng Plaza B, NO.8 Zhongguancun East Road, Haidian Dist,


Phone: 86-10-82526466
Fax: 86-10-82526963

News Articles [17 Associated News Articles listed on BioPortfolio]

Arix Bioscience Plc - Director/PDMR Shareholding

Arix Bioscience Plc - Director/PDMR Shareholding PR Newswire London, June 11 ARIX BIOSCIENCE PLC Director/PDMR Shareholding Arix Bioscience plc today announces the annual award of nil cost options...

Kazia Therapeutics (KZA) - GDC-0084 Phase II underway

Edison Investment Research - Pharmaceutical & healthcare - Kazia Therapeutics: Kazia Therapeutics has initiated the dose optimization lead-in component of the Phase II trial of GDC-0084 in glioblastom...

Vis Mundi Increases Shareholding in EgySwiss Group to Controlling Stake After Capital Injection ...

<!-- <style id='antiClickjack'>body{display:none !important;} if (self === top) { var antiClickjack = document.getElementById('antiClickjack'); antiClickjack.parentNode.removeChild(antiClic...

LCT to sell JV shares for $3 million and receive Diabecell licence

New Zealand-based Living Cell Technologies has agreed to sell its 50% shareholding in joint venture company,…

Alex P. Guidi Reports Increased Shareholding in Coronado Resources Ltd.

Following these recent purchases, Mr. Guidi now beneficially owns 587,913 common shares and 300,000 common share purchase warrants. If all of Mr. Guidi's common share Read more...

Shire plc: Director/PDMR Shareholding

Director/PDMR ShareholdingMarch 12, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG)Notification of transactions by persons discharging managerial responsibilities+--+------------------------------------...

German dialysis specialist divests majority shares in Sound Inpatient for $2.15B

Fresenius Medical Care sold its majority shareholding in Sound Inpatient Physicians Holdings to an investment consortium for  -More- 

Nanobiotix 2017 Annual Results

Regulatory News: This press release features multimedia. View the full release here: Updated composition of Nanobiotix shareholding struct...

Drugs and Medications [0 Results]


PubMed Articles [1 Associated PubMed Articles listed on BioPortfolio]

Study on the ownership balance and the efficiency of mixed ownership enterprises from the perspective of heterogeneous shareholders.

Based on the database data of Chinese industrial enterprises from 2000 to 2007 and the LP method, this paper measures the total factor productivity of enterprises and investigates the effect of differ...

Clinical Trials [0 Results]


Companies [6 Associated Companies listed on BioPortfolio]

Chengzhi Shareholding Co.,Ltd

Chengzhi Shareholding Co.,Ltd was established on October 8. 1998 in Nanchang, Currently the total asset is 922.18 millions Yuan with 27 subsidiary companies. The company currently has more than 1900 e...

Cool Logistics Ltd

Cool Logistics is based in the UK and is focused on delivering temperature controlled packaging throughout Europe. We have manufacturing facilities in several European countries and are ISO Certified....

Tridelta plc

Tridelta plc is the Parent Company of Tridelta Development Limited, which specialises in the Research, Development, Manufacturing and Marketing of Diagnostic Products for application principally withi...


The NOACK Group of Companies was founded in 1980 as NOACK SA. in Ascona, Switzerland, by Mr. Dieter Noack. The main focus was distribution of products into the feed and agrofood industries.Starting fr...

Dalian Chemphy Chemical Co.,Ltd

Dalian Chemphy Chemical Co., Ltd. (Chemphy) is a technology-based shareholding enterprise invested by Dalian Institute of Chemical Physics (DICP, affiliated to Chinese Academy of Sciences), Dalian Jin...

More Information about "Chengzhi Shareholding Co.,Ltd" on BioPortfolio

We have published hundreds of Chengzhi Shareholding Co.,Ltd news stories on BioPortfolio along with dozens of Chengzhi Shareholding Co.,Ltd Clinical Trials and PubMed Articles about Chengzhi Shareholding Co.,Ltd for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chengzhi Shareholding Co.,Ltd Companies in our database. You can also find out about relevant Chengzhi Shareholding Co.,Ltd Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record